Life-changing medical research embraces the power of art
Posted: 15 August 2023 Fantastical, mystical and mesmerising, the 2023 Art of Science exhibition presents the most fascinating scientific art from some of Australia’s most creative and visionary researchers, working to solve the world’s most complex medical challenges. WEHI’s 2023 Art of Science online gallery offers you the chance to be…
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform
Posted: 11 August 2023 Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion Biosystems, the pioneer in molecular Magnetic Resonance Imaging (MRI) dedicated to changing the way we…
Atmo Biosciences recruits first patients in dysmotility pivotal clinical study
Posted: 11 August 2023 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced it has commenced a pivotal clinical study to assess the use of…
Laboratory space available for lease Close to Monash University
Posted: 11 August 2023 Cartherics Pty Ltd built new laboratories in 2022/23 at Notting Hill Victoria just North of Monash University. The available area is a totally separate laboratory space of 155 m2 and 70 m2 open plan…
Soap made using ingredients from Country. Tested using Merck technology.
Posted: 11 August 2023 Merck travelled to the Northern Territory with the DeadlyScience team to pilot the first DeadlyLabs kit. It’s a project led by Indigenous Elders in the Robinson River region to share their knowledge, their ideas,…
Firebrick Phase 3 Trial Fully Recruited with 500 Subjects
Posted: 11 August 2023 Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of…
EXO-OVARIAN CANCER SCREENING PROGRAM COMPLETES SERUM EQUIVALENCE STUDY
Posted: 11 August 2023 INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, today announced results from an equivalence study to evaluate exosome-based biomarkers and performance of the EXO-OC test algorithm…
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Posted: 11 August 2023 Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the imaging of prostate cancer using positron…
SUCCESSFUL COMPLETION OF SECOND PLANNED DSMB REVIEW OF ACTION3 PHASE 3 FSGS KIDNEY TRIAL
Posted: 11 August 2023 Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, today confirmed that the independent Data Safety Monitoring Board (DSMB) has successfully concluded a second review of the ACTION3 phase…
Firebrick Covid-19 Trial Achieves Primary Endpoint
Posted: 7 August 2023 Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray (“Nasodine”) in COVID-19 achieved its primary endpoint. The primary endpoint was the reduction in viral…
Adherium Accelerates Commercialisation with Largest US Allergy & Asthma Practice
Posted: 7 August 2023 Leading digital health company Adherium Limited (ASX:ADR) has signed a collaboration agreement with US–based Allergy Partners to transform asthma management for its more than 300,000 patients across 130 sites in 20 states. Allergy Partners…
AD-214 RETURNS TO CLINICAL STUDIES
Posted: 7 August 2023 AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products using its i-body platform provides an update on its lead fibrosis asset, AD-214. The first participants in the Company’s Phase I…
